Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I-II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter Study.
31-gene expression profile
cutaneous melanoma
personalized medicine
prospective
stage I–II
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Feb 2022
19 Feb 2022
Historique:
received:
14
12
2021
revised:
28
01
2022
accepted:
15
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Fifteen to forty percent of patients with localized cutaneous melanoma (CM) (stages I-II) will experience disease relapse. The 31-gene expression profile (31-GEP) uses gene expression data from the primary tumor in conjunction with clinicopathologic features to refine patient prognosis. The study's objective was to evaluate 31-GEP risk stratification for disease-free survival (DFS) in a previously published cohort with longer follow-up. Patients with stage IB-II CM ( A Class 2B result was a significant predictor of 3-year DFS (hazard ratio (HR) 8.4, The 31-GEP is a significant predictor of disease relapse in patients with stage IB-II melanoma and accurately stratified patients by risk of relapse.
Sections du résumé
BACKGROUND
BACKGROUND
Fifteen to forty percent of patients with localized cutaneous melanoma (CM) (stages I-II) will experience disease relapse. The 31-gene expression profile (31-GEP) uses gene expression data from the primary tumor in conjunction with clinicopathologic features to refine patient prognosis. The study's objective was to evaluate 31-GEP risk stratification for disease-free survival (DFS) in a previously published cohort with longer follow-up.
METHODS
METHODS
Patients with stage IB-II CM (
RESULTS
RESULTS
A Class 2B result was a significant predictor of 3-year DFS (hazard ratio (HR) 8.4,
CONCLUSIONS
CONCLUSIONS
The 31-GEP is a significant predictor of disease relapse in patients with stage IB-II melanoma and accurately stratified patients by risk of relapse.
Identifiants
pubmed: 35205808
pii: cancers14041060
doi: 10.3390/cancers14041060
pmc: PMC8870692
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondo de Investigaciones Sanitarias
ID : P.I. 12/00840, PI15/00956 and 15/00716
Organisme : CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain
ID : co-funded by "Fondo Europeo de Desarrollo Regional (FEDER). Unión Europea. Una manera de hacer Europa"
Organisme : Catalan Government, Spain
ID : AGAUR 2009 SGR 1337 and AGAUR 2014_SGR_603
Organisme : Fundació La Marató de TV3, 201331-30
ID : grant
Organisme : European Commission
ID : 6th Framework Programme, Contract nº: LSHC-CT-2006-018702 (GenoMEL)
Organisme : CERCA Programme / Generalitat de Catalunya
ID : Research Grant
Organisme : Castle Biosciences, Inc.
ID : N/A
Références
J Eur Acad Dermatol Venereol. 2019 May;33(5):857-862
pubmed: 30702163
BMC Cancer. 2018 Feb 5;18(1):130
pubmed: 29402264
Am J Surg. 2021 Jun;221(6):1195-1199
pubmed: 33773750
J Clin Aesthet Dermatol. 2020 Nov;13(11 Suppl 1):s3-s14
pubmed: 33349788
JAMA Dermatol. 2017 Feb 1;153(2):225-226
pubmed: 28002545
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591-6
pubmed: 26042651
JCO Precis Oncol. 2021 Apr 06;5:
pubmed: 34036233
J Am Acad Dermatol. 2019 Jan;80(1):149-157.e4
pubmed: 30081113
Cancer Med. 2019 May;8(5):2205-2212
pubmed: 30950242
Dermatol Surg. 2018 Dec;44(12):1494-1500
pubmed: 29994951
Int J Cancer. 2016 Dec 15;139(12):2722-2729
pubmed: 27563839
Clin Cancer Res. 2015 Jan 1;21(1):175-83
pubmed: 25564571
Melanoma Res. 2020 Jun;30(3):279-285
pubmed: 30106842
N Engl J Med. 2021 Jun 10;384(23):2229-2240
pubmed: 34107182